Publication | Closed Access
Antibodies to Epstein-Barr Virus in Nasopharyngeal Carcinoma, Other Head and Neck Neoplasms, and Control Groups<xref ref-type="fn" rid="FN2">2</xref>
404
Citations
0
References
1970
Year
ImmunodeficienciesImmunologyPathologyEast AfricaNasopharyngeal CarcinomaImmunotherapyOral CancerCancer-associated VirusEpstein-barr VirusNasopharyngeal CancerNpc PatientsNeck OncologyRadiation OncologyCancer ResearchLymphoid NeoplasiaControl GroupsMedicineHistopathologyCancer DiagnosisImmune SurveillanceMalignant DiseaseHepatitisHead And Neck CancerOncology
Sera from patients with head and neck neoplasms, nonneoplastic disease, and healthy donors across East Africa, Hong Kong, India, and France were tested for Epstein‑Barr virus antibodies by indirect immunofluorescence, and the results were later correlated with clinical and histological diagnoses. High anti‑EBV antibody titers were found in 84 % of nasopharyngeal carcinoma patients (geometric mean 1:348), rising with disease stage, whereas patients with other head and neck cancers and controls showed only 13 % high titers and a geometric mean of 1:36, underscoring a strong association between EBV seropositivity and nasopharyngeal carcinoma.
Sera collected in East Africa, Hong Kong, India, and France from patients with head and neck neoplasms, patients with nonneoplastic disease, and donors in apparently good health were titrated for antibodies to the Epstein-Barr virus (EBV) by the indirect immunofluorescence technique. The results were correlated with the clinical and histological diagnoses which, as a rule, became available only after performance of the tests. Of 235 East African and Chinese patients who were classified as cases of nasopharyngeal carcinoma (NPC), 84% had high anti-EBV liters (≧ 1:160) and the geometric mean level was 1:348. The histopathology, whether described as anaplastic carcinoma or not, poorly or moderately well-differentiated, squamous or epidermoid carcinoma, seemed irrelevant. When the NPC patients from Hong Kong were grouped according to the stage of their disease, the incidence of high anti-EBV titers increased successively from 45% in stage I to ultimately 100% in stage V. The geometric mean titers rose correspondingly from 1:103 in the initial to 1:788 in the final stages. In contrast, patients with neoplasms (mainly carcinomas) arising in sites of the head and neck other than the nasopharnyx revealed a sixfold lower incidence of high titers (13%) and a nearly tenfold lower geometric mean level (1:36). Assortment of these patients as to the sites and types of their neoplasms revealed no significant differences in the distribution of anti-EBV levels among the groups so obtained. The incidence of high tilers and the geometric mean level among controls resembled those in patients with neoplasms other than NPC. The significance and implications of these findings are discussed.